Sign inCreate account

Report workspace tools

NCT05225961COMPLETEDanonymous

Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment

Sponsor

Source record

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Acute Ischemic Stroke

Indication / condition

AI-normalized

Acute Ischemic Stroke

Intervention

Source record

Tirofiban, Acetylsalicylic acid

Source & freshness

Source record

NCT ID

NCT05225961

Original source

ClinicalTrials.gov

Source last updated

Apr 03, 2026

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05225961

Title

Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Status

COMPLETED

Phase

PHASE4

Condition raw

Acute Ischemic Stroke

Condition normalized

Acute Ischemic Stroke

Modality raw

Acute Ischemic Stroke

Modality normalized

small molecule

Target raw

Acute Ischemic Stroke

Target normalized

Acute Ischemic Stroke

Interventions

Tirofiban, Acetylsalicylic acid

Public preview

Source record

The ATILA trial evaluates the effectiveness and safety of Tirofiban versus intravenous Aspirin in patients with acute ischemic stroke due to tandem lesions, undergoing endovascular treatment. This study aims to establish a protocol for antiplatelet therapy in this patient population, potentially leading to improved outcomes and reduced complications.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05225961

Status

COMPLETED

Phase

PHASE4

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Executive brief

Investment-Ready Snapshot

The ATILA trial evaluates the effectiveness and safety of Tirofiban versus intravenous Aspirin in patients with acute ischemic stroke due to tandem lesions, undergoing endovascular treatment. This study aims to establish a protocol for antiplatelet therapy in this patient population, potentially leading to improved outcomes and reduced complications.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 03, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05225961

Indication

Acute Ischemic Stroke

Modality

small molecule

Target

Acute Ischemic Stroke

Intervention

Tirofiban, Acetylsalicylic acid

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.